100 F
San Fernando
Saturday, Apr 20, 2024

Sienna Biopharmaceuticals to Cease Operations

Sienna Biopharmaceuticals Inc. will cease operations by the end of the week and lay off its remaining employees, according to a filing Wednesday with the Securities and Exchange Commission. The decision comes after the Westlake Village company filed for Chapter 11 in September and sought to sell its topical pre-treatment drug for laser hair removal of light hair, SNA-001, in October. According to a report from the Wall Street Journal, acne therapy company Sebacia agreed to pay $1.7 million in cash for SNA-001, beating out another offer made by California-based dermatologist Mitchel Goldman with an offer of $1.65 million. The sale is due to close by Friday. There were no bids for Sienna’s other drugs, including flagship topicals SNA-120 for psoriasis and SNA-125 for atopic dermatitis. Shares of Sienna plummeted 4 cents, or 34 percent, on Thursday, bringing the price to 8 cents on the Nasdaq. The company rang the bell on the Nasdaq Market Site in Times Square on its first day of trading about two and a half years ago; shares of Sienna closed up $4.25, or more than 28 percent, to $19.25 on opening day. The company was originally founded in Delaware as Sienna Labs in July 2010, and was last cited as employing 18 individuals at its 7,000-square-foot headquarters at 30699 Russell Ranch Road.

Featured Articles

Related Articles